Immuneering/IMRX

$6.43

0.62%
-
1D1W1MYTD1YMAX

About Immuneering

Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. Its platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Ticker

IMRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Benjamin Zeskind

Employees

67

Headquarters

Cambridge, United States

Immuneering Metrics

BasicAdvanced
$189.08M
Market cap
-
P/E ratio
-$1.87
EPS
-
Beta
-
Dividend rate

What the Analysts think about Immuneering

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
191.6% upside
High $25.00
Low $10.00
$6.43
Current price
$18.75
Average price target

Immuneering Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-12.5M
3.31%
Profit margin
0%
-

Immuneering Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 12.91%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.50
-$0.51
-$0.43
-$0.43
-
Expected
-$0.58
-$0.56
-$0.53
-$0.49
-$0.47
Surprise
-13.15%
-8.93%
-18.48%
-12.91%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Immuneering stock

Buy or sell Immuneering stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing